Premium
Bioavailability of L ‐DOPA from HP‐200—a Formulation of Seed Powder of Mucuna pruriens (Bak): a Pharmacokinetic and Pharmacodynamic Study
Author(s) -
Mahajani S. S.,
Doshi V. J.,
Parikh K. M.,
Manyam B. V.
Publication year - 1996
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/(sici)1099-1573(199605)10:3<254::aid-ptr809>3.0.co;2-e
Subject(s) - mucuna pruriens , pharmacokinetics , cmax , bioavailability , oral administration , pharmacology , pharmacodynamics , chromatography , high performance liquid chromatography , pharmacognosy , absorption (acoustics) , chemistry , medicine , traditional medicine , biological activity , materials science , biochemistry , in vitro , composite material
HP‐200, a formulation made from the seed powder of Mucuna pruriens , contains among other constituents, about 4% L ‐DOPA. After five normal human volunteers were each given a single oral dose of 30 g of HP‐200, plasma samples were obtained at 0, 20, 40, 60, 90, 120, 180, 240 and 360 min for assay of L ‐DOPA by HPLC technique using electrochemical detection. The supine systolic and diastolic blood pressures were recorded at each sampling time. The results indicate that on oral administration, L ‐DOPA was absorbed from HP‐200 with plasma peak levels ( C max =1.56±0.163 μg/mL) achieved at T max =83±16.09 min. The plasma half life was 102±2 min and the auc was determined as 6.508±0.421 μg/h/mL. The pharmacokinetic profile of HP‐200 exhibited characteristics similar to formulations of synthetic L ‐DOPA, except for the lack of a sharp peak. HP‐200, a new herbal formulation, appears to be suitable for the treatment of Parkinson's disease.